Compare AbbVie Inc (ABBV) vs Kinross Gold Corporation (KGC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AbbVie Inc vs Kinross Gold Corporation — how do they compare? AbbVie Inc trades at $247.56 (market cap $441.94B), while Kinross Gold Corporation trades at $27.51 (market cap $32.29B). The key difference: AbbVie Inc is far larger — about 13.7× Kinross Gold Corporation's market cap, and AbbVie Inc pays the higher dividend (2.77%). Which is the better fit depends on your goals.
| ABBV | KGC | |
|---|---|---|
Market Cap | $441.94B | $32.29B |
Sector | Health | Basic Materials |
52-Week High | $263.58 | $38.06 |
52-Week Low | $197.38 | $18.70 |
Enterprise Value | $506.19B | $30.37B |
Dividend Yield | 2.77% | 0.59% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $249.9, up 0.8% on the day, with strong analyst support (29 Buy, 1 Sell) and a $278.69 consensus price target. Recent quarterly earnings have consistently beaten estimates, driven by robust immunology drug sales. The stock shows a bullish technical trend, supported by moving averages, and the company maintains solid cash flow and dividend payments.
Outlook is positive with revenue growth and pipeline advancements, though high P/E and debt levels pose risks. The stock offers a compelling buy case for growth and income investors, balanced by execution and patent expiry challenges ahead.
Kinross Gold (KGC) trades at $27.59, up 0.69% with strong fundamental momentum. The company demonstrates robust earnings growth with three consecutive quarterly beats and impressive profitability metrics including 37.52% net margin and 36.95% ROE. Recent S&P upgrade to 'BBB' and positive project developments at Lobo-Marte support the bullish analyst consensus.
Outlook remains positive with 29 analysts showing 58.6% buy ratings and $37.20 consensus target, representing 35% upside. Key risks include gold price volatility and execution challenges at new projects. Strong free cash flow generation and disciplined capital allocation support continued shareholder returns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About Kinross Gold Corporation
Kinross Gold is a Canada-based senior gold producer, producing roughly 2.4 million gold equivalent ounces in 2020. The company had 30 million ounces of proven and probable gold reserves and 59 million ounces of silver reserves at the end of 2020. It operates mines and focuses its greenfield and brownfield exploration in the Americas, West Africa, and Russia. The company has historically used acquisitions to fuel expansion into new regions and production growth.
Read more on KGC →
